Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: SANOFI

Market Cap 88.98B 102B 82.41B 77.15B 145B 9,630B 146B 978B 379B 4,740B 383B 375B 16,459B P/E 2026 *
11x
P/E 2027 * 10.3x
Enterprise Value 99.79B 114B 92.42B 86.52B 162B 10,799B 163B 1,096B 425B 5,315B 430B 420B 18,457B EV / Sales 2026 *
2.12x
EV / Sales 2027 * 1.94x
Free-Float
89%
Yield 2026 *
5.74%
Yield 2027 * 6.08%
Manager TitleAgeSince
Chief Executive Officer 64 2026-04-30
Director of Finance/CFO 64 2024-03-31
Chief Tech/Sci/R&D Officer 51 2023-09-10
Director TitleAgeSince
Director/Board Member 60 2019-04-29
Director/Board Member 56 2020-04-27
Director/Board Member 64 2020-04-27
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 102B
-1.21%-3.04%+44.03%+143.07% 980B
-2.48%-5.18%+52.47%+39.15% 550B
-2.14%-4.94%+16.83%+57.08% 382B
+0.25%-3.09%+23.33%+16.04% 316B
+0.61%-1.69%+27.35%+13.73% 272B
+0.22%-3.10%+24.67%+30.49% 268B
+4.59%+1.98%-38.43%-46.26% 199B
-1.19%-4.95%+16.68%+47.69% 182B
-1.35%-1.46%+14.06%+59.26% 154B
Average -0.27%-3.02%+20.11%+40.03% 366.93B
Weighted average by Cap. -0.76%-3.68%+29.49%+63.31%

Financials

2026 *2027 *
Net sales 47.07B 53.98B 43.59B 40.81B 76.53B 5,094B 77B 517B 200B 2,507B 203B 198B 8,706B 49.98B 57.32B 46.29B 43.33B 81.27B 5,409B 81.76B 549B 213B 2,662B 215B 211B 9,244B
Net income 8.15B 9.34B 7.54B 7.06B 13.24B 881B 13.32B 89.49B 34.68B 434B 35.07B 34.31B 1,507B 8.95B 10.27B 8.29B 7.76B 14.56B 969B 14.65B 98.39B 38.13B 477B 38.55B 37.73B 1,656B
Net Debt 10.8B 12.39B 10.01B 9.37B 17.57B 1,169B 17.67B 119B 46B 575B 46.51B 45.51B 1,998B 8.08B 9.27B 7.49B 7.01B 13.14B 875B 13.22B 88.81B 34.42B 431B 34.8B 34.05B 1,495B
Logo SANOFI
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (81.8%): prescription drugs for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases; - human vaccines (18.2%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas. At the end of 2025, the group had 37 production sites worldwide. Net sales are distributed geographically as follows: France (3.9%), Europe (17.1%), the United States (50.8%), China (6%) and other (22.2%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AA
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!